CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞生产过程中优化代谢以提高疗效
英文原题：Optimization of metabolism to improve efficacy during CAR-T cell manufacturing.
查看英文原题
Optimization of metabolism to improve efficacy during CAR-T cell manufacturing.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞（CAR-T 细胞）疗法是一种相对较新、有效且快速发展的过继免疫疗法。尽管其在血液系统恶性肿瘤中取得了显著疗效，但仍有一些问题有待解决。例如，复发率高，在实体瘤中疗效不佳。在这篇综述中，我们首先简要描述T细胞的代谢重编辑以及CAR-T 细胞制备过程中代谢的变化。此外，我们总结了改善CAR-T 细胞体外和体内代谢适应性及抗肿瘤活性的最新进展和新策略。
展开英文摘要原文
Chimeric antigen receptor T cell (CAR-T cell) therapy is a relatively new, effective, and rapidly evolving therapeutic for adoptive immunotherapies. Although it has achieved remarkable effect in hematological malignancies, there are some problems that remain to be resolved. For example, there are high recurrence rates and poor efficacy in solid tumors. In this review, we first briefly describe the metabolic re-editing of T cells and the changes in metabolism during the preparation of CAR-T cells.
Furthermore, we summarize the latest developments and newest strategies to improve the metabolic adaptability and antitumor activity of CAR-T cells in vitro and in vivo.
论文信息
- 作者
- Zhang M、Jin X、Sun R、Xiong X、Wang J、Xie D、Zhao M
- 第一作者单位
- First Center Clinical College, Tianjin Medical University, Tianjin, 300192, China.China
- 通讯作者单位
- Department of Hematology, Tianjin First Central Hospital, Tianjin, 300192, China. mingfengzhao@sina.com.China
- 文献类型
- 非美国政府资助研究 · 综述
- 期刊
- Journal of translational medicine2021 Dec 7
- 原文标识
- PubMed 34876185 · DOI 10.1186/s12967-021-03165-x
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →